GlobeStar Therapeutics Accounts Payable

GlobeStar Therapeutics's accounts payable stands at $660K as of June 2024. That compares with $490K in the prior-year period — up 35.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

GlobeStar Therapeutics reported $660K in accounts payable versus $490K a year earlier — a 35.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $490K in the prior-year period — up 35.2% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how GlobeStar Therapeutics's accounts payable evolved across reporting periods, while the comparison chart places GSTC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Industrials, accounts payable is commonly used to spot outliers. GlobeStar Therapeutics's reading of $660K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.